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Summary.-In mice with a transplantable mammary carcinoma, treatment with
the prostaglandin-synthesis inhibitors flurbiprofen or indomethacin produced
various beneficial effects. Survival time after excision of the transplanted tumour
was increased, particularly when the drugs were given with the chemotherapeutic
agents methrotrexate and melphalan, and there were more disease-free survivors.
The combined treatment with flurbiprofen also gave less tumour recurrence at the
excision site. Flurbiprofen did not seem to alter the bioavailability of the chemo-
therapeutic agents.
OUR previous studies in mice with a
transplanted mammary adenocarcinoma
showed beneficial effects of the prosta-
glandin-synthesis (PGS) inhibitor flurbi-
profen (FLU) (Bennett et al., 1978, 1979,
1981; Berstock et al., 1979). Mice treated
with this drug had smaller resected
tumours and lived longer than controls.
The tumour was insensitive to the chemo-
therapeutic drugs melphalan (1.4 mg/kg)
and methotrexate (2 mg/kg) but when
FLU was also given the preliminary
results indicated prolongation of survival
and inhibition of local recurrence after
tumour excision (Bennett et al., 1979).
Work published by others around that
time showed a greater anti-cancer effect
on a rat chlorambucil-resistant tumour
when FLU was given with chlorambucil
(Powles et al., 1978). We now report
various experiments in mice. Four studies
used FLU and chemotherapy, 3 compared
indomethacin and FLU, and other studies
were made on tumour prostaglandins and
the mechanism of FLU action.
MATERIAL AND METHODS
The NC tumour used is a transplantable
adenocarcinoma which originally arose spon-
taneously in the mammary gland of a WHT/
Ht mouse; it has been passaged subsequently
in this inbred strain, and appears to be oflow
immunogenicity (Hewitt et al., 1976). The
mice were injected with 106 NC carcinoma
cells into the left flank, as described pre-
viously (Bennett et al., 1979) and the tumours
wN-ere excised 2-3 weeks later under anaes-
thesia with ether or, in some experiments,
pentobarbitone. All test drugs were adminis-
tered orally in syrup, the experiments
lasting too long to permit twice-daily
injections or gastric intubation. In some
experiments mice were weighed at least
weekly, starting at tumour transplantation,
to monitor drug-induced clhanges in body
weight. Post-mortem examinations wrere car-
ried out in all mice given tumour, to assess
the incidence of distant metastases (mainly
in the lungs and mediastinum) and recur-
rence at the site of tumour excision.
Results are expressed as medians with
semiquartile ranges in parentheses, unless
stated otherwise, and analysed statistically
using the Mann-Whitney U-test, Fisher's
exact probability, or, for survival, the method
of Lee & Desu (1972) (SPSS, London Uni-
versity Computer).
Mouse survival and tumour recurrence
(a) Effects of chemotherapy+FLU.-In 4
separate studies we used 250 female micePROSTAGLANDINS AND CANCER
- 2-4 months old and 25-30 g in weight.
FLU or control treatment was started on Day
13 after tumour transplantation, and each
tumour was excised on Day 14. In each
study the mice were divided into 4 groups
and treated as follows:
(1) Controls (0.1 ml raspberry syrup or
50% syrup BP daily).
(2) Chemotherapy (methotrexate (2 mg/
kg) or melphalan (1.4 mg/kg) daily
on Days 1-3, 8-10 and 15-17 after
tumour excision).
(3) FLU (2.5 mg/kg) twice daily.
(4) Combination of (2) and (3).
Treatment with FLU or syrup continued
until the animals died or were killed on
humane grounds, if death from cancer was
imminent, or until Day 121 when the experi-
ments were terminated.
(b) Comparison of FLU and indomethacin
given with chemotherapy.-There were 3
separate studies on 173 male mice 2-4
months old, 30-40 g in weight. Syrup alone
(57 mice) or containing indomethacin (INDO)
(1.25 mg/kg, 58 mice) or FLU (2.5 mg/kg,
58 mice) was given twice daily by mouth,
starting the day before tumour transplanta-
tion. The tumours were excised at 3 weeks,
and the chemotherapeutic drugs were started
the next day, in the doses shown in (a).
The excised tumours were cut finely,
washed and homogenized in Krebs solution
(Bennett et al., 1973) and extracted for
prostaglandins with organic solvents (Unger
et at., 1971). The extracts were assayed
against prostaglandin E2 on rat gastric
fundus (Bennett et al., 1973) which quantifies
the prostaglandin-like activity, but does not
distinguish between different fatty acids. At
the time of tumour excision in one of these
studies (9 or 10 mice/group), a cut was made
and sutured in the contralateral flank.
Both sutured sites were later examined for
the appearance of tumour.
Bioavailability ofthe chemotherapeutic drugs
Two studies were undertaken to investigate
the possibility that FLU increased the bio-
availability of the chemotherapeutic drugs.
In the first study, normal non-tumour-
bearing WHT/Ht female mice (total, 98)
were given 4, 8 or 16 times the previous
doses of methotrexate (MTX) and melphalan
(L-PAM) on Days 1-3 and 8-10 (respectively
8 and 5-6 mg/kg; 16 and 11-2 mg/kg; or
32 and 22-4 mg/kg). Half the mice in each
group were given FLU (2-5 mg/kg) twice
daily.
In the second study, normal female mice
in 3 separate experiments were given MTX
(2 mg/kg) and L-PAM (1.4 mg/kg) daily for
3 days, with or without FLU (2.5 mg/kg)
twice daily. The mice were killed 1 h after
the last dose of drugs by inhalation of ether,
blood was removed from the inferior vena
cava after opening the abdomen, and the
plasma from groups of 3 mice was pooled
and frozen at -20°C. Free and bound
MTX were measured in mouse plasma by
radio-immunoassay (courtesy of Dr W.
Aherne, University of Surrey).
RESULTS
Mouse survival and tumour recurrence
(a) Effect of chemotherapy and FLU.-
The tumours in these female mice showed
a weak tendency to respond to the chemo-
therapeutic drugs alone, as shown by
survival time and tumour recurrence at
the excision site (Table I, Fig. 1). How-
ever, partly because of a particularly good
effect in 1 of the 4 studies, the median
survival time in mice started on FLU
alone just before tumour excision was
20% longer than controls, and there were
more disease-free survivors at 120 days.
Of particular interest, those given FLU
plus chemotherapy survived 42% longer
than controls, more mice were disease-
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FIG. 1. Survival in groups of female mice
following tumour resection. In descending
order: FLU+chemotherapy 0, FLU 0,
chemotherapy V, control V. Horizontal
axis, days after tumour excision. See
Table I for more details and statistical
significance.
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TABLE I.-Female mice from Expt a. The cancer was insensitive to chemotherapy
alone, as judged by survival time, the numbers of survivors and local recurrence. Mice
givenflurbiprofen (FLU) alone lived longer and more were alive at the endof the experi-
ment (all disease-free). Mice given FLU with chemotherapy survived longer still, and
had less local recurrence of tumour at the excision site. *P< 0-05; **P< 0-005. Survival
time is shown as medians, with semiquartile ranges in parentheses
Group
Control
Chemo
FLU
FLU+chemo
Survival
n (days)
51 45 (35-57)
72 49 (38-69)
56 54 (42-118)*
71 63(46-109)**
free at the end ofthe study, and there was
a 48% lower incidence of local recurrence
at the excision site. The numbers of mice
with lung metastases at the time of death
were similar, but the treated animals
lived longer and therefore had more
time for the metastases to develop.
(b) Comparison of FLU and INDO
given with chemotherapy.-Those male
mice given INDO alone from the time of
tumour transplantation, or chemotherapy
alone from the time of tumour excision,
had median survival times increased by
13% and 15% respectively (Table II, Fig.
2). Survivalwasfurtherincreasedbygiving
INDO or FLU with the chemotherapy,
and there were 4 disease-free survivors at
120 days in the group given chemotherapy
and INDO. However, there was no signi-
ficant effect on survival with FLU alone
(P< 0 6). The numbers of mice with
recurrent tumour at the excision site
were not significantly affected by any
drug treatment alone but tended to be
120-day
survivors Local
recurrence
No disease Total (%)
4 7 61
9 10 45
15* 15 46
16* 16 21**
days
FIG. 2.-Survival in groups of male mice
following tumour resection. In descending
order: (INDO+chemotherapy V =FLU+
chemotherapy *), chemotherapy 0,
INDO V, FLU E1, controls Q. Horizontal
axis, days after tumour excision. See
Table II for further details and statistical
significance.
less in the group given FLU and chemo-
therapy (Table II). No tumour occurred
in any contralateral cut made when the
primary cancer was excised.
Mice treated with INDO tended to have
smaller excised tumours, but there was
TABLE II.-Male mice from Expt b. Mice given chemotherapy or indomethacin (INDO)
alone lived longer than controls. *P< 0 1; **P< 0-05; ***P< 0-0001. Survival, shown
as medians with semiquartile ranges in parentheses, was even longer when chemotherapy
was given with INDO or FLU (both P< 0-05) than with chemotherapy alone
Group
Control
Chemo
FLU
INDO
FLU+chemo
INDO +chemo
Survival
n days
28 53 (47-58)
28 61 (55-69)**
28 53 (49-60)
29 60 (50-68)**
27 69 (62-73)***
29 69 (58-85)***
Local
Disease-free recurrence
survivors (%)
0 64
0 74
0 71
0 68
0 37*
4 55
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TABLE III.-Indomethacin (INDO) or
flurbiprofen (FLU) reduced the amount
of prostaglandin-like material extracted
from homogenates ofmale mouse primary
tumours, the reduction being greater
with INDO than with FLU (P <0-01).
There was a slight tendency for the drugs
to reduce tumour size. Tumour prosta-
glandins are given in PGE2 equivalents.
All results expressed as medians with
semiquartile ranges in parentheses.
*P<01; **'*P< 00001 compared to
controls
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Tumour
prostaglandins
(ng/g)
62 (44-95)
3-5 (0-8)***
8 (419)***
little effect with FLU (Table III). Both
drugs reduced tumour prostaglandins,
but the effect was greater with INDO
(Table III).
Lack ofeffect oftreatments on body weight.
-In 3 experiments with female mice
started on FLU the day before tumour
excision at 2 or 3 weeks, and given the
chemotherapeutic drugs on Days 1-3,
8-10 and 15-17 after surgery, body-
weight changes were similar in all groups.
Table IV shows the result of 1 experiment.
TABLE IV.-Body weights of female mice
(8 mice/group). Tumours were implanted
on Day 1 and resected on Day 22 under
ether anaesthesia. Drug treatments were
begun on Day 21 (FLU) and Day 23
(chemotherapy). Body-weight changes were
similar throughout. The weights increased
initially, andfelltemporarily aftersurgery
and the start of chemotherapy. Similar
results were obtained in two other ex-
periments
% wt increase at day:
,K A~~~
8 15 22 29 36
8 9 15 9 12
5 11 17 11 17
4 11 18 10 19
6 11 20 18 22
FiG. 3.-Mice were given FLU (0) or
vehicle control (Q) with chemotherapy
(CT) in doses 4, 8 and 16 times higher than
those used in the other experiments. CT 4,
8 and 16 were respectively MTX (8, 16 and
32 mg/kg), and L-PAM (5-6, 11-2 and 22-4
mg/kg), given orally on Days 1-3 and 8-10.
FLU had no significant effect on mouse
survival (vertical axis). Those not dying
earlier were killed on Day 21.
Toxicity and bioavailability of the chemo-
therapeutic drugs.-In the first experi-
ment we assumed that if FLU increased
the bioavailability of the chemothera-
peutic drugs, it would increase the toxicity
in normal mice (unless FLU simul-
taneously protected against toxicity). In
mice given high doses of L-PAM and
MTX with or without FLU, death from
drug toxicity was similar (Fig. 3). In the
second experiment, radio-immunoassays
of mouse plasma showed that the per-
centage free MTX was similar in controls
and in mice given FLU (63.8 + 3-2 (s.e.)
in 5 groups of 3 mice, and 65-6 + 1 0, in
6 groups of 3 mice respectively).
DISCUSSION
The present results generally confirm
and extend our previous preliminary
findings. In WHT/Ht mice FLU alone
can prolong survival of mice transplanted
with NC adenocarcinomas, but does not
affect the incidence of local recurrence at
the excision site. The NC carcinoma is
weakly sensitive to L-PAMa nd MTX;
the chemotherapeutic drugs alone had
no significant effect on tumour size
Group
Control
INDO
FLU
0
0 0
000 @0.
16
Tumour wt
(mg)
281 (185-457)
250 (150-339)*
263 (177-408)
Controls
FLU
Chemo
FLU+chemo
51
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(Bennett et al., 1979) and the present
results show at best a moderate effect on
survival time. These doses are near to the
maximum tolerated, since double or
quadruple amounts caused 1 and 18
deaths respectively out of 57 and 59
female mice (unpublished). However,
chemotherapy combined with FLU in-
creased survival and the numbers of
disease-free mice at the end ofthe studies,
and reduced local recurrence at the
excision site. Powles et al. (1978) found
that FLU enhanced the effect of chloram-
bucil in rats with a chlorambucil-resistant
tumour, and that it improved the response
in 3 patients resistant to chemotherapy.
Tumour frequently recurred at the
excision site, but not in the contralateral
incision. Local recurrence was therefore
probably due to malignant cells left
behind in the region of the primary
tumour, rather than to trapping of
circulating malignant cells in the wound.
The anticancer mechanism was not
due to altered caloric intake, since the
treatments did not affect body weight.
FLU did not seem to act by displacing
MTX from plasma protein-binding sites
(as occurs with chlorambucil and phenyl-
butazone, Schiffman et al., 1978). How-
ever, the measurements were made only
4 h after giving the FLU, and we have not
examined the possibility that the chemo-
therapy increases the bioavailability of
FLU. Binding studies were not done
with melphalan, because no sensitive
assay was available at that time. Survival
in normal mice given high-dose chemo-
therapy with or without FLU was similar,
so FLU either did not increase the bio-
availability of the chemotherapeutic
agents, or it simultaneously protected
against their toxicity. Powles & Millar
(1979) found that INDO reduced the
toxicity of MTX to gut and bone in rats.
Our results in mice given INDO alone
or with chemotherapy largely agree with
those using FLU. The increased survival
after tumour excision also agrees with
some other studies using INDO alone
(Lynch et al., 1978; Trevisani et al.,
1980). However, in contrast to our pre-
vious results (Bennett et al., 1978, 1979,
1981; Berstock et al., 1979) INDO or
FLU caused little reduction in tumour
size. One difference is that the present
experiments were in male mice, but later
(unpublished) experiments in female mice
also show little reduction of tumour size
with FLU. A more likely explanation is
that the tumour characteristics have
changed with repeated passaging. For
example, the cancer may now be more
aggressive (H. E. Hewitt, personal com-
munication).
Since INDO and FLU are both potent
inhibitors of prostaglandin synthesis (as
confirmed by us) the overall similarity of
their anticancer effects strengthens the
possibility that prostaglandins are in-
volved. Perhaps these drugs lessened a
prostaglandin-induced inhibition of the
immune system (Plescia et al., 1975).
Although the NC carcinoma is thought to
have low immunogenicity (Hewitt et al.,
1976) FLU tended to increase the lym-
phocyte content oftumours (Leaper et al.,
1979). With regard to tumour spread,
aspirin is antimetastatic in mice, possibly
due to inhibition of platelet aggregation
(Gasic et al., 1973). Other speculations
are that the drugs inhibited the formation
or dilatation of tumour blood vessels, so
reducing either tuimour metabolism or the
escape of malignant cells into the blood-
stream. Or perhaps the drugs remove a
"cytoprotective" effect (Robert, 1979)
on cancer cells. Both drugs also have
other actions, such as inhibition of
calcium binding by cell membranes
(Northover, 1973).
These findings have far-reaching clinical
implications. FLU or INDO might im-
prove the response of cancer patients to
chemotherapy or radiotherapy. Cancer
patients may take PGS inhibitors for
various ailments, and aspirin may even
be prescribed to relieve effects of cancer
treatment, such as diarrhoea after pelvic
irradiation (Mennie et al., 1975) or muco-
sitis (O'Connor et al., 1977; Tanner, et al.,
1981). Other drugs which can inhibit
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PGS include the anti-oestrogen tamoxifen
(Ritchie, 1978) and the corticosteroid
prednisone (Gryglewski et al., 1975).
The many types of prostaglandins, and
the differences between tumours and
aspects of their development, make it
likely that prostaglandins can exert both
good and bad effects in cancer (see
Bennett, 1979, 1982). Furthermore,
PGS inhibitors can divert metabolism of
prostaglandin precursors into lipoxy-
genase products (Higgs et al., 1980) whose
actions in cancer are not known. How-
ever, most in vivo studies of laboratory
animals indicate that PGS inhibitors are
beneficial in cancer, and contrary claims
by 1 group (Favalli et al., 1980; Hofer
et al., 1980) are open to substantial
criticism (see Bennett, 1982).
PGS inhibitors, seem to be safe for the
gastric mucosa in rats when given with
cytotoxic drugs. Indeed, L-PAM and
MTX surprisingly reduced the gastric
mucosal damage by aspirin (Berstock
et al., 1980) possibly by increasing the
formation of "cytoprotective" prosta-
glandins. Nevertheless, before recom-
mending the administration of PGS in-
hibitors to cancer patients, it is important
to demonstrate their safety and efficacy
in different types and stages of human
cancer. Our double-blind controlled trials
with flurbiprofen now in progress in cancer
of the breast, and of the head and neck,
will help answer these questions. If
non-steroidal anti-inflammatory drugs are
advantageous, this would represent a
major advance in therapy with relatively
safe drugs.
We thank Dr W. Aherne for the methotrexate
assays, the AIRC and CRC for financial support, the
Upjohn Company for prostaglandins, The Boots
Company Ltd for flurbiprofen, and Merck, Sharpe
and Dohme for indomethacin.
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